Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

346 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
TP53 mutations in advanced colorectal cancer: the dark side of the moon.
Pietrantonio F, Biondani P, Perrone F, Di Bartolomeo M, Pacifici M, Milione M, Melotti F, Maggi C, Montemurro G, Bossi I, Mariani L, de Braud F. Pietrantonio F, et al. Oncology. 2014;86(5-6):289-94. doi: 10.1159/000360088. Epub 2014 Jun 7. Oncology. 2014. PMID: 24924261
BRAF codons 594 and 596 mutations identify a new molecular subtype of metastatic colorectal cancer at favorable prognosis.
Cremolini C, Di Bartolomeo M, Amatu A, Antoniotti C, Moretto R, Berenato R, Perrone F, Tamborini E, Aprile G, Lonardi S, Sartore-Bianchi A, Fontanini G, Milione M, Lauricella C, Siena S, Falcone A, de Braud F, Loupakis F, Pietrantonio F. Cremolini C, et al. Among authors: pietrantonio f. Ann Oncol. 2015 Oct;26(10):2092-7. doi: 10.1093/annonc/mdv290. Epub 2015 Jul 7. Ann Oncol. 2015. PMID: 26153495 Free article.
Single-Agent Panitumumab in Frail Elderly Patients With Advanced RAS and BRAF Wild-Type Colorectal Cancer: Challenging Drug Label to Light Up New Hope.
Pietrantonio F, Cremolini C, Aprile G, Lonardi S, Orlandi A, Mennitto A, Berenato R, Antoniotti C, Casagrande M, Marsico V, Marmorino F, Cardellino GG, Bergamo F, Tomasello G, Formica V, Longarini R, Giommoni E, Caporale M, Di Bartolomeo M, Loupakis F, de Braud F. Pietrantonio F, et al. Oncologist. 2015 Nov;20(11):1261-5. doi: 10.1634/theoncologist.2015-0171. Epub 2015 Oct 7. Oncologist. 2015. PMID: 26446234 Free PMC article.
Location of Primary Tumor and Benefit From Anti-Epidermal Growth Factor Receptor Monoclonal Antibodies in Patients With RAS and BRAF Wild-Type Metastatic Colorectal Cancer.
Moretto R, Cremolini C, Rossini D, Pietrantonio F, Battaglin F, Mennitto A, Bergamo F, Loupakis F, Marmorino F, Berenato R, Marsico VA, Caporale M, Antoniotti C, Masi G, Salvatore L, Borelli B, Fontanini G, Lonardi S, De Braud F, Falcone A. Moretto R, et al. Among authors: pietrantonio f. Oncologist. 2016 Aug;21(8):988-94. doi: 10.1634/theoncologist.2016-0084. Epub 2016 Jul 5. Oncologist. 2016. PMID: 27382031 Free PMC article.
Heterogeneity of Acquired Resistance to Anti-EGFR Monoclonal Antibodies in Patients with Metastatic Colorectal Cancer.
Pietrantonio F, Vernieri C, Siravegna G, Mennitto A, Berenato R, Perrone F, Gloghini A, Tamborini E, Lonardi S, Morano F, Picciani B, Busico A, Volpi CC, Martinetti A, Battaglin F, Bossi I, Pellegrinelli A, Milione M, Cremolini C, Di Bartolomeo M, Bardelli A, de Braud F. Pietrantonio F, et al. Clin Cancer Res. 2017 May 15;23(10):2414-2422. doi: 10.1158/1078-0432.CCR-16-1863. Epub 2016 Oct 25. Clin Cancer Res. 2017. PMID: 27780856 Free article.
TRIBE-2: a phase III, randomized, open-label, strategy trial in unresectable metastatic colorectal cancer patients by the GONO group.
Cremolini C, Marmorino F, Loupakis F, Masi G, Antoniotti C, Salvatore L, Schirripa M, Boni L, Zagonel V, Lonardi S, Aprile G, Tamburini E, Ricci V, Ronzoni M, Pietrantonio F, Valsuani C, Tomasello G, Passardi A, Allegrini G, Di Donato S, Santini D, Falcone A; all the investigators of the Gruppo Oncologico del Nord Ovest. Cremolini C, et al. Among authors: pietrantonio f. BMC Cancer. 2017 Jun 9;17(1):408. doi: 10.1186/s12885-017-3360-z. BMC Cancer. 2017. PMID: 28599628 Free PMC article. Clinical Trial.
Selecting patients for gastrectomy in metastatic esophago-gastric cancer: clinics and pathology are not enough.
Fornaro L, Fanotto V, Musettini G, Uccello M, Rimassa L, Vivaldi C, Fontanella C, Leone F, Giampieri R, Rosati G, Lencioni M, Santini D, Di Donato S, Tomasello G, Brunetti O, Pietrantonio F, Bergamo F, Scartozzi M, Avallone A, Lutrino SE, Melisi D, Antonuzzo L, Pellegrino A, Gerratana L, Cordio S, Vasile E, Aprile G. Fornaro L, et al. Among authors: pietrantonio f. Future Oncol. 2017 Oct;13(25):2265-2275. doi: 10.2217/fon-2017-0246. Epub 2017 Oct 4. Future Oncol. 2017. PMID: 28976226
Vinorelbine in BRAF V600E mutated metastatic colorectal cancer: a prospective multicentre phase II clinical study.
Cremolini C, Pietrantonio F, Tomasello G, Dadduzio V, Moretto R, Morano F, Schirripa M, Antoniotti C, Fucà G, Bergamo F, Rossini D, Nichetti F, Ziampiri S, Ghidini M, Marmorino F, Prisciandaro M, Falcone A, De Braud F, Loupakis F, Lonardi S. Cremolini C, et al. Among authors: pietrantonio f. ESMO Open. 2017 Aug 10;2(3):e000241. doi: 10.1136/esmoopen-2017-000241. eCollection 2017. ESMO Open. 2017. PMID: 29209533 Free PMC article.
The PANDA study: a randomized phase II study of first-line FOLFOX plus panitumumab versus 5FU plus panitumumab in RAS and BRAF wild-type elderly metastatic colorectal cancer patients.
Battaglin F, Schirripa M, Buggin F, Pietrantonio F, Morano F, Boscolo G, Tonini G, Lutrino ES, Lucchetti J, Salvatore L, Passardi A, Cremolini C, Arnoldi E, Scartozzi M, Pella N, Boni L, Bergamo F, Zagonel V, Loupakis F, Lonardi S. Battaglin F, et al. Among authors: pietrantonio f. BMC Cancer. 2018 Jan 25;18(1):98. doi: 10.1186/s12885-018-4001-x. BMC Cancer. 2018. PMID: 29370781 Free PMC article. Clinical Trial.
346 results